Clinical effi ciency of pemetrexed in the treatment of advanced retreated non-small cell lung cancer / 中国癌症杂志
China Oncology
;
(12)2006.
Artigo
em Chinês
| WPRIM
| ID: wpr-546494
ABSTRACT
Background and purpose:
Pemetrexed is a multitargeted anti-metabolite. Pemetrexed has been approved as the second-line treatment in non-small cell lung cancer. Our aim was to evaluate the clinical effi ciency and toxicity of pemetrexed in treatment of advanced retreated non-small cell lung cancer.Methods:
17 advanced retreated NSCLC patients received pemetrexed at a dose of 500 mg/m2, the chemotherapy was repeated every 21 days on two cycles until progressive disease or untolerant adverse effects.Results:
Among 17 patients, the overall response rate was 11.8%, the clinical benefi t rate was 76.5%, and the main toxicity was hematological toxicties.Conclusions:
Pemetrexed is effective in treatment of advanced retreated non-small lung cancer and the toxicity can be well tolerated.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
China Oncology
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS